In a report released today, Soumit Roy from JonesTrading reiterated a Buy rating on Surface Oncology (SURF), with a price target of $12.00. The company’s shares closed last Thursday at $2.72.
According to TipRanks.com, Roy is a 4-star analyst with an average return of 10.2% and a 34.0% success rate. Roy covers the Healthcare sector, focusing on stocks such as Adaptimmune Therapeutics, Monopar Therapeutics Inc, and Aeglea Biotherapeutics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Surface Oncology with a $12.00 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $5.09 and a one-year low of $1.15. Currently, Surface Oncology has an average volume of 148.3K.
Based on the recent corporate insider activity of 7 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of SURF in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Surface Oncology, Inc. is a clinical-stage immuno-oncology company, which focuses on biological pathways critical to the immunosuppressive tumor microenvironment and the development of next-generation cancer therapies. The company was founded by David S. Grayzel in 2014 and is headquartered in Cambridge, MA.
